BiotechTube

Recombinant human acid sphingomyelinase

Phase 1Completed
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Human Acid Sphingomyelinase Deficiency

Conditions

Human Acid Sphingomyelinase Deficiency

Trial Timeline

Mar 1, 2013 → Jan 1, 2014

NCT ID
NCT01722526

About Recombinant human acid sphingomyelinase

Recombinant human acid sphingomyelinase is a phase 1 stage product being developed by Sanofi for Human Acid Sphingomyelinase Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT01722526. Target conditions include Human Acid Sphingomyelinase Deficiency.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01722526Phase 1Completed

Competing Products

20 competing products in Human Acid Sphingomyelinase Deficiency

See all competitors
ProductCompanyStageHype Score
Influenza vaccine, split inactivatedComac MedicalPhase 1
25
CS-8958 + CS-8958 + oseltamivir phosphateDaiichi SankyoPhase 3
77
GSK1265744 30mg + Placebo + GSK1265744 5mgShionogiPhase 2
52
DolutegravirShionogiPhase 3
77
GSK1349572 + efavirenzShionogiPhase 2
52
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
33
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
33
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mgShionogiPhase 1
33
GSK1349572 (dolutegravir) + raltegravirShionogiPhase 3
77
Ortho-Cyclen + Dolutegravir + PlaceboShionogiPhase 1
33
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
33
dolutegravirShionogiPhase 3
77
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placeboShionogiPhase 3
77
GSK1349572 + EfavirenzShionogiPhase 1
33
GSK1349572ShionogiPhase 1
33
GSK1349572 + PlaceboShionogiPhase 2
52
Dolutegravir + MethadoneShionogiPhase 1
33
GSK1349572 + Raltegravir + GSK1349572 Placebo + Raltegravir PlaceboShionogiPhase 3
77
GSK1349572 + Rifampin + RifabutinShionogiPhase 1
33
DTG + BCV + TVRShionogiPhase 1
33

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84